Dalbavancin (CAS 171500-79-1)
See product citations (1)
QUICK LINKS
Dalbavancin is a lipoglycopeptide antibiotic that inhibits cell wall synthesis in bacteria. It functions by binding to the D-alanyl-D-alanine terminus of the peptidoglycan precursor, preventing its incorporation into the growing bacterial cell wall. This disrupts the integrity of the cell wall, leading to cell lysis and ultimately bacterial death. Dalbavancin′s mechanism of action involves interfering with the transglycosylation and transpeptidation steps of peptidoglycan synthesis, inhibiting the cross-linking of peptidoglycan chains and weakening the bacterial cell wall. This disruption of cell wall synthesis is bactericidal against a broad spectrum of Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and Streptococcus pyogenes. Dalbavancin′s mechanism of action may be an effective for studying bacterial cell wall synthesis and for investigating potential targets for antibiotic development.
Dalbavancin (CAS 171500-79-1) References
- Dalbavancin: a review. | Scheinfeld, N. 2007. Drugs Today (Barc). 43: 305-16. PMID: 17724497
- Dalbavancin. | Anderson, VR. and Keating, GM. 2008. Drugs. 68: 639-48; discussion 649-51. PMID: 18370443
- Dalbavancin in the treatment of different gram-positive infections: a real-life experience. | Bouza, E., et al. 2018. Int J Antimicrob Agents. 51: 571-577. PMID: 29180276
- Dalbavancin for the management of osteomyelitis: a major step forward? | Almangour, TA. and Alhifany, AA. 2020. J Antimicrob Chemother. 75: 2717-2722. PMID: 32457989
- Dalbavancin and telavancin in the treatment of infective endocarditis: a literature review. | Lampejo, T. 2020. Int J Antimicrob Agents. 56: 106072. PMID: 32629114
- Role or oritavancin and dalbavancin in acute bacterial skin and skin structure infections and other potential indications. | Bassetti, M., et al. 2021. Curr Opin Infect Dis. 34: 96-108. PMID: 33405480
- Dalbavancin treatment for prosthetic joint infections in real-life: a national cohort study and literature review. | Matt, M., et al. 2021. J Glob Antimicrob Resist. 25: 341-345. PMID: 33962065
- Dalbavancin for the Treatment of Prosthetic Joint Infections: A Narrative Review. | Buzón-Martín, L., et al. 2021. Antibiotics (Basel). 10: PMID: 34072670
- Real-World Use of Dalbavancin in the Era of Empowerment of Outpatient Antimicrobial Treatment: A Careful Appraisal Beyond Approved Indications Focusing on Unmet Clinical Needs. | Gatti, M., et al. 2021. Drug Des Devel Ther. 15: 3349-3378. PMID: 34376971
- Dalbavancin. | Barberán, J., et al. 2021. Rev Esp Quimioter. 34 Suppl 1: 26-28. PMID: 34598419
- Dalbavancin treatment for spondylodiscitis: multi-center clinical experience and literature review. | Ramadan, MS., et al. 2022. J Chemother. 34: 360-366. PMID: 34923922
- Clinical Pharmacokinetics and Pharmacodynamics of Dalbavancin. | Molina, KC., et al. 2022. Clin Pharmacokinet. 61: 363-374. PMID: 34931283
- Evaluating the Use of Dalbavancin for Off-Label Indications. | Taylor, K., et al. 2022. Infect Dis Rep. 14: 266-272. PMID: 35447884
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Dalbavancin, 1 mg | sc-391787 | 1 mg | $131.00 |